SLHN:SIXSwiss Life Holding AG Analysis

Swiss Life is trading at CHF 846.6, comfortably above the identified support of CHF 833 and well below the resistance of CHF 935, with the 20‑day, 50‑day and 200‑day SMAs (CHF 883.7, CHF 879.7 and CHF 871.2) all sitting above the current price, signaling a bullish technical backdrop. RSI at 46.3 suggests the stock is neither overbought nor oversold, while the MACD histogram remains negative (‑2.59) indicating short‑term momentum weakness despite an overall bullish trend direction. Volume is increasing, and 30‑day volatility of roughly 19 % is moderate; the beta of 0.28 (computed) or 0.54 (quote) points to low sensitivity to market swings. Fundamentally, the company’s DCF fair value of CHF 2,951 dwarfs the market price, implying a deep undervaluation gap, while the PE of 19.5 and PB of 3.35 are modest for an insurer with solid profitability (gross margin 34.7 %, operating margin 16.5 %). The balance sheet shows ample cash (CHF 83.7 bn) offsetting debt (CHF 14.9 bn) and a high debt‑to‑equity ratio driven by cash holdings, with ROE at 16.6 % and ROA modest at 0.5 %. No dividend is paid, and free cash flow is currently negative, reflecting ongoing investment or acquisition activity.
Geographically diversified across Switzerland, France, Germany, the UK and Luxembourg, Swiss Life benefits from stable regulatory environments but must navigate sector‑specific oversight. The modest revenue growth of 1.1 % and strong operating cash flow support a resilient earnings base, while the low beta and increasing volume suggest manageable risk. Given the sizable valuation discount, strong cash position, and stable earnings, the stock presents an attractive entry point for investors with a medium‑to‑long‑term horizon, albeit with caution on short‑term momentum and free‑cash‑flow constraints.